New targeted drug shows promise for Hard-to-Treat leukemia
NCT ID NCT02337829
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called acalabrutinib in 48 adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had a specific high-risk genetic change (deletion 17p). Some participants had already tried other treatments, while others were newly diagnosed. The goal was to see how well the drug shrank or controlled the cancer by blocking a key protein (BTK) that helps cancer cells grow. Results were measured using standard response criteria.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Bethesda, Maryland, 20892, United States